A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...
PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of...
Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...
A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...
The A5322 protocol is a long-term observational study, with a planned series of analyses of data to be collected from an...
